Drug Discovery World

JULY 11, 2022

The global cell and gene therapy (CGT) market reached a value of ~$4 billion in 2020 and is expected to grow to ~$34 billion by 2030 1. Methods& clinical development, 21,524–529. " Critical Considerations For Packaging And Delivery Of Gene Therapy Products." Molecular therapy. link] omtm.2021.04.001.

Therapies 130

Therapies Clinical Trials Production Trials 130

The Pharma Data

NOVEMBER 5, 2020

Key Pipeline Progress Regeneron has more than 20 product candidates in clinical development, including five marketed products for which it is investigating additional indications. Updates from the clinical pipeline include: Dupixent ® (dupilumab). Non-GAAP net income per share – diluted (1). $. Business Highlights.

Production 52

Production FDA FDA Approval Trials 52

Codon

MARCH 24, 2024

In the case of semaglutide, those cells are Saccharomyces cerevisiae— also known as Baker’s yeast — engineered to secrete a peptide precursor that is later purified, chemically modified, packaged into an injectable or tablet form, and then shipped around the world. The real cost is clinical development.

Engineering 87

Engineering Vaccine Production RNA 87